Select Bibliography

Filter by any of these (after searching):

Singh, Baljit

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 5 items

Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Campbell, Jeffrey I. , Yau, Christina , Krass, Polina , Moore, Dan ... - - Breast Cancer Res Treat - 2017

Manuscript - Secondary - Primary - Breast - CALGB-150007

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Esserman, Laura J. , Berry, Donald A. , Cheang, Maggie C. U. ... - - Breast Cancer Res Treat - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance)

Sikov, William M. , Barry, William T. , Hoadley, Katherine A. ... - SABCS - Cancer Res - 2015

Abstract - Secondary - Primary - Breast - CALGB-40603

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

Sikov, William M , Berry, Donald A , Perou, Charles M , Singh, Baljit ... - SABCS - Cancer Res - 2016

Abstract - Secondary - Primary - Breast - CALGB-40603

CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)

Sikov, William M , Polley, Mei-Yin C , Twohy, Erin L ... - ASCO - J Clin Oncol - 2019

Abstract - Secondary - Primary - Breast - CALGB-40603